China grants conditional approval for Pfizer's oral COVID-19 drug
BEIJING - China's drug regulator on Friday granted conditional approval for the imports of Pfizer's Paxlovid COVID-19 pill.
The pill is a small-molecule oral drug, a co-package of antiviral drugs nirmatrelvir tablets and ritonavir tablets, for adults who are experiencing mild to moderate COVID-19 symptoms and who are at a higher risk of becoming more seriously ill, according to the National Medical Products Administration.
It can be given to patients who, for instance, are in old age or have chronic renal diseases, diabetes, cardiovascular diseases, and chronic lung diseases.
Patients should take the medicine as prescribed by the doctors and pay close attention to drug interactions, according to the administration.
The administration asked the drug's marketing authorization holder to continue its relevant research work, fulfill the conditions within the specified time and submit the following research results timely.
- Third rare earth mineral found in Bayan Obo deposit
- Tracing Flying Tigers' historical sites in mountainous China
- Senior official urged public security system to contribute more in new development pattern
- Guangdong prepares as Typhoon Wipha approaches
- China-Laos Railway doubles daily cross-border passenger services
- China's top political advisors discuss macroeconomic performance in H1
